Édition française
ACS
Slides and resources
Antiplatelet therapies
Antiplatelet Therapy During PCI
Antiplatelet trials in 2008
The FellowShip Series: Late stent thrombosis
Stent thrombosis and antiplatelet therapy
Antithrombotic therapy: A year in review
More...
High-risk ACS
Update on STEMI
Optimizing outcomes
Steering Committee Members
2007 ACC/AHA UA/NSTEMI GUIDELINES
Horizons AMI
More...
Other ACS programs
Antiplatelet therapy for atherothrombotic disease
Acute STEMI: Overcoming Peri-Procedural Challenges in Patients Undergoing PCI
Optimal pharmacological management of STEMI
Optimizing patient outcomes in CAD
More...
HeartWire
Generic clopidogrel in Europe
ACUITY: Bivalirudin switching data
ACS guideline discrepancies
GI events and clopidogrel
Intracoronary spectroscopy catheter approved
More...
Cardiometabolic risk
Resource center
Abdominal obesity
Cardiometabolic Risk in the Spotlight
Taming abdominal obesity
Abdominal obesity: The perfect storm of CVD and diabetes
Prevention and lifestyle interventions to minimize CV risk
More...
Dysglycemia
Keys to prevention in diabetes and CV risk
Test your knowledge on risk assessment and intervention for patients with dysglycemia
Charting the course of CV risk in diabetes
Running the race against CV risk in diabetes
More...
HeartWire
Carotid bruits and CVD
Preventing diabetes in hypertensives
Triglycerides and CHD patients
BP-related disease neglected
Thiazolidinediones and fractures
More...
Clinical cardiology
Slides and resources
Difficult cases in coronary interventions
Atherothrombosis
US and European ACS guidelines
Antiplatelet therapy for atherothrombotic disease
Adjunctive pharmacology in PCI
Risk/Benefit or Benefit/Risk?
Antiplatelet Therapy Across the Cardiovascular Risk Spectrum
More...
HeartWire
GI events and clopidogrel
Depression and HF
Palliative care in heart failure and cancer
Thiazolidinediones and fractures
Remote monitoring helps HF patients not tied to home
More...
Dyslipidemia
Low HDL-C: Survey
Slides and resources
Mixed dyslipidemia
Attenuating risk... treatment beyond LDL
Steering Committee Members
More...
HeartWire
Statins associated with increased progression of AMD, but caution is urged
Intensive atorvastatin
Niacin/laropiprant not approvable
ACHIEVE enrollment on hold
More...
Electrophysiology
Cardiac rhythm management
Remote monitoring: Creating a clinical consensus
Advances in remote monitoring
More...
HeartWire
Largest study on ICDs in kids
Denervation for CPVT
Risks of early repolarization
Digitek digoxin tablets recalled
Osteoporosis drug promotes atrial fib
More...
Heart failure
HeartWire
Depression and HF
Palliative care in heart failure and cancer
Remote monitoring helps HF patients not tied to home
Digitek digoxin tablets recalled
Precipitating factors affect CHF outcomes
More...
Hypertension
HeartWire
Preventing diabetes in hypertensives
BP-related disease neglected
Mice lacking angiotensin weigh less
More...
Interventional cardiology
Slides and resources
Drug-eluting stents
Economics of DES vs BMS
The disappearing stent: Bioabsorbable stents
The FellowShip Series: Late stent thrombosis
SCAI-ACCi2 2008: What's hot in interventional cardiology?
Challenging cases: Lower limb intervention
More...
HeartWire
ACUITY: Bivalirudin switching data
ACS guideline discrepancies
GI events and clopidogrel
Disclosure inconsistent across stent research
Intracoronary spectroscopy catheter approved
More...
Prevention
CV Risks - Survey #3
CV Risks - Survey #2
Slides and resources
CV Risks - Survey
Cardiovascular risks
Stories of 2007-the year in review
Variable conclusions of meta-analyses of RAS inhibition. What's a clinician to believe?
CKD and CVD: Examining strategies for target organ protection and CV risk reduction
Will new trials provide definitive answers?
Life saving drugs in life threatening situations
More...
HeartWire
Carotid bruits and CVD
Largest study on ICDs in kids
WAFACS: No benefit to homocysteine lowering
Inflammatory markers predict CHF
Never too late to stop
More...
HeartWire
News for the CV healthcare professional by theheart.org journalists
ACUITY: Bivalirudin switching data
Carotid bruits and CVD
ACS guideline discrepancies
FDA expands "extracellular matrix" biomaterial indications
Natale heads up new arrhythmia institute in Austin
Largest study on ICDs in kids
Hormone therapy linked to stroke risk regardless of timing of initiation
Denervation for CPVT
Risks of early repolarization
GI events and clopidogrel
More...
Editorial series
A series of discussions among editorial leaders, developed by theheart.org
HeartBeat
Nissen. Califf. Rosiglitazone.
More...
The Cardiology Show
Surrogate end points on trial
AHA 2007
From disease treatment to health promotion
More...
Cardiology panels
From evidence to practice
The lowdown on HORIZONS
DES debate continues
Back to the ABCs for CHF?
Women and ACS
More...
HeartWire clips
On moving to industry: An interview with Dr Terry Ferguson
Face-to-face interviews
The Braunwald interview: TRITON-TIMI 38
DES showdown: Serruys vs Virmani
The Braunwald interview
More...
The EP show
Recall Reality
More...
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
TRITON-TIMI 38 and ILLUMINATE
More...
CME programs
Accredited educational programs, supported by industry, developed by theheart.org
Acute coronary syndromes
Antiplatelet Therapy During PCI
Antiplatelet trials in 2008
Update on STEMI
Stent thrombosis and antiplatelet therapy
Optimizing outcomes
More...
Cardiometabolic risk
Cardiovascular disease: call to action for the cardiologist
Cardiometabolic Risk in the Spotlight
Taming abdominal obesity
Abdominal obesity: The perfect storm of CVD and diabetes
More...
Clinical cardiology
US and European ACS guidelines
Adjunctive pharmacology in PCI
Risk/Benefit or Benefit/Risk?
Current and emerging therapies in the management of VTE
More...
Dyslipidemia
Measuring plaque regression by statins
Attenuating risk... treatment beyond LDL
Statins in heart failure: What's new? - A Canadian perspective
More...
Electrophysiology
Improving outcomes in AF
More...
Heart Failure
Hyponatremia: Clinical challenges and unmet needs
Renal dysfunction in ADHF: Examining new strategies
More...
Hypertension
RAPiHD and more: Combination therapy in severe hypertension
MAU: marker of renal compromise AND heart disease
Optimizing Synergistic Effects in Antihypertensive Therapy
CV Protection: Beyond hypertension
A SMARTer approach to renal disease
More...
Interventional cardiology
Economics of DES vs BMS
The disappearing stent: Bioabsorbable stents
Slides and resources
The FellowShip Series: Late stent thrombosis
Decision 2008: The art and science of DES
More...
Prevention
Stories of 2007-the year in review
Variable conclusions of meta-analyses of RAS inhibition. What's a clinician to believe?
CV Risks - Survey #3
Statins and the vasculature
CKD and CVD: Examining strategies for target organ protection and CV risk reduction
More...
Academic series
Duke Clinical Medicine Series
Sponsored education
Promotional educational programs developed under the direction of our sponsors
Branded infosites
Actos
Lovaza
Central Blood Pressure Resource Center
Condition infosites
Atrial Fibrillation infosite
Promotional educational programs
Endothelin receptor antagonists
Tirofiban in STEMI
CREATE annual meeting
CORONA study results
RecordAF Registry: An international, observational, prospective survey assessing the control of Atrial Fibrillation
Press Center
Forum
In-depth discussions, moderated by Dr Melissa Walton-Shirley
Heparin contamination was deliberate act to cut costs?
Managed-care data suggest high frequency of GI events from clopidogrel
Vascular benefits of stopping smoking are rapid
WAFACS published: No CVD benefit in longest-duration folic-acid/B-vitamin supplementation study
Enoxaparin now affected by heparin contaminant
More...
The Fellows' corner
Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?
Dr Eric Topol
invites you to share your opinions.
Click here to view the video blog and join the discussion.
HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with
heart
wire
news and features editor
Larry Husten
,
Dr Terry Ferguson
muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the
American College of Cardiology Scientific Sessions
.
Dr Valentin Fuster
moderates this frank and sometimes heated discussion on the results of
ENHANCE
,
STRADIVARIUS
,
ONTARGET
, and
PERISCOPE
, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join
Drs Eric J Topol
and
Robert M Califf
in a discussion of the many issues surrounding
ENHANCE
and
ACCORD
.
Question
Do you think the ACC and SCAI should continue to combine their annual meetings in future years?
(See:Arranged marriage: Funding and "cultural differences" may dictate whether SCAI-ACC/i2 stay hitched)
No
Yes
Vote
HeartWire
Sort by:
Section
Date
Title
Show:
Titles
Titles and summaries
Jump to:
Acute coronary syndromes
Dyslipidemia
Cardiometabolic risk
Clinical cardiology
Electrophysiology
Heart failure
Hypertension
Interventional cardiology
Prevention
News
At the AHA
At the ESC
Cardiology ink
Features
HeartWire clips
History
IndustryPulse
Lab notes
MediaPulse
Medscape Medical News
Murmurs
NetWise
The entrepreneur
The skeptic
Verbatim
Voices of cardiology
Page:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
Showing:
1 - 25
of
7847
documents.
HeartWire > Acute coronary syndromes
ACS patients in India: Younger, poorer, sicker, and dying
Apr 24, 2008 18:30 EDT
/ A new registry analysis of almost 21 000 STEMI and non-STEMI patients admitted to Indian hospitals suggests that the country, along with other developing nations, is in dire need of better emergency services, healthcare insurance, and public-education campaigns if any dint is to be made in the global CVD epidemic. (Xavier D et al.
Lancet
2008; 371:1435-1442.)
No increased in-hospital mortality in AMI patients arriving during "off" hours
Apr 21, 2008 16:00 EDT
/ AMI patients arriving at US hospitals on weeknights, holidays, or weekends were more likely to receive fibrinolysis and less likely to undergo PCI, but they were no more likely to die in the hospital than patients coming in on weekdays. (Jneid H et al.
Circulation
; published online before print April 21, 2008.)
AHA promotes chest-compression-only bystander-initiated CPR
Mar 31, 2008 16:00 EDT
/ The public is now urged to start chest compressions on any adult who collapses suddenly; mouth-to-mouth ventilation is sanctioned only for rescuers with both the training and the confidence to do it right. (Sayre MR et al.
Circulatio
n
; published online before print March 31, 2008.)
Progress in pre-PCI clopidogrel dosing: Increases can be based on platelet reactivity
Mar 29, 2008 19:30 EDT
/ A small randomized trial opens the door to the prospect of individualized pre-PCI clopidogrel dosage increases to overcome "resistance" to the antiplatelet drug; patients with the titrated dosage increases had fewer clinical events over 30 days. (American College of Cardiology 2008 Scientific Sessions.)
ACS patients do better in clinical-trial hospitals
Mar 26, 2008 14:15 EDT
/ Hospitals that participate in clinical trials appear to provide better care for ACS patients, a new study suggests. (Majumdar SR et al.
Arch Intern Med
2008; 168:657-662.)
Secondary prevention: Benefits extend to elderly
Mar 25, 2008 16:15 EDT
/ A contemporary study following elderly MI patients has shown improvements in mortality over a decade, with around a 3% reduction in deaths per year. The results are probably due to increased use of cardiovascular medications and should encourage doctors to make sure they apply evidence-based interventions to all eligible patients, say the researchers. (Setoguchi S et al.
J Am Coll Cardiol
2008; 51:1247-1254.)
New statement on cocaine-associated MI urges caution with beta blockers, emphasizes kicking the habit
Mar 17, 2008 16:00 EDT
/ The evaluation and management of patients who develop chest pain or MI after using cocaine should mirror that of patients who have not used cocaine, but with several important caveats. (McCord J et al.
Circulation
; published online before print March 17, 2008.)
Streamlined "CPR" by EMS can improve survival in out-of-hospital cardiac arrest
Mar 12, 2008 18:00 EDT
/ The technique emphasizes chest compressions and early IV epinephrine while reducing the role of assisted ventilation. (Bobrow BJ et al.
JAMA
2008; 299:1158-1165.)
Stay in touch: Postdischarge contact with MI patients boosts adherence to meds
Mar 11, 2008 17:00 EDT
/ Especially beta blockers, two separate studies suggest. (Daugherty SL et al. Smith DH et al.
Arch Intern Med
2008; 168:485-491, 477-483.)
No easy way to predict which ACS patients will require CABG
Mar 6, 2008 12:00 EST
/ The biggest determinants of CABG appear to be racial and regional factors, so that decisions about upstream antithrombotic use are best made locally, a new study concludes. (Chew DP et al.
Am Heart J
; published online before print February 21, 2008.)
Marijuana use associated with increased risk of mortality among acute MI patients
Mar 3, 2008 17:15 EST
/ Marijuana use by acute MI survivors is associated with a threefold higher risk of mortality after infarction, and a nearly fourfold increase in death from noncardiovascular causes. (Mukamal KJ et al.
Am Heart J
2008; 155:465-470.)
Stem-cell therapy in CV disease: Review finds "modest benefit with little toxicity"
Feb 28, 2008 10:45 EST
/ LV functional gains are limited but enough to make a clinical difference, the author says. (Burt RK et al.
JAMA
2008; 299:925-936.)
Disparities in awareness of MI symptoms
Feb 22, 2008 16:15 EST
/ A survey in 14 US states has found that less than a third of adults are aware of all five warning signs and symptoms of MI and would call 911 as their first response. There were variations in awareness between races and between the sexes and also by geographic region and education. (Fang J et al.
MMWR Morb Mortal Wkly Rep
; published online February 22, 2008.)
Baxter heparin now officially in short supply
Feb 21, 2008 12:30 EST
/ The product has now been added to the FDA's list of drug shortages, while investigations into the adverse reactions have revealed that one Chinese supplier was not inspected by the FDA because of a name mix-up.
Higher blood transfusion rates for ACS patients in the US, but no reductions in death/MI
Jan 8, 2008 15:15 EST
/ Mounting concern that blood transfusions may do more harm than good is particularly germane in the US, where, according to a new analysis, patients with ACS may be significantly more likely to undergo blood transfusions than non-US patients yet see no corresponding benefits in terms of reduced death or MI. (Rao S et al.
Am J Cardiol
2008; 101:25-29.)
Better exercise counseling needed for CHD patients
Jan 8, 2008 10:15 EST
/ Patients with heart disease are less likely to comply with physical-activity recommendations than subjects without heart disease, a new study shows. (Zhao G et al.
Am J Cardiol
; published online before print December 21, 2007.)
What initial dose of aspirin is right for STEMI patients?
Dec 20, 2007 12:15 EST
/ An initial dose of 162-mg aspirin may be as effective as and perhaps safer than 325 mg for the acute treatment of ST-elevation MI, a new study suggests. (Berger JS et al.
Circulation
; published online before print December 17, 2007.)
New data look promising for rivaroxaban
Dec 12, 2007 15:30 EST
/ Two phase 3 trials with the new oral anticoagulant rivaroxaban suggest it is more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery. (American Society of Hematology 2007 Annual Meeting.)
AHA, ACC update management guidelines for ST-elevation MI
Dec 12, 2007 10:15 EST
/ The new and modified treatment recommendations account for, among other things, recent revelations about COX-2 inhibitor safety and the new abundance of antithrombin agents. (Antman EM et al.
Circulation
;
J Am Coll Cardiol
; published online before print December 11, 2007.)
Mortality after bleeding in MI patients lower in real world than in clinical trials?
Nov 28, 2007 16:30 EST
/ Although bleeding may be causally related to adverse outcomes in some patients in the real-world setting, it is often merely a marker for patients at higher risk for adverse outcomes, the GRACE investigators suggest. (Spencer FA et al.
Circulation
; published online before print November 19, 2007.)
GIK therapy no benefit in STEMI, possible harm
Nov 27, 2007 16:00 EST
/ The latest in a long line of trials to show no benefit of high-dose glucose-insulin-potassium infusion as an adjunctive treatment in patients with STEMI has been published. Combining the new data with an older trial, the researchers also found a suggestion of possible early harm with GIK. (Diaz R et al.
JAMA
2007; 298:2399-2405.)